# A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases

> **NCT01378975** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 146 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT01378975
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01378975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01378975, "A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01378975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*